JAN 13, 2020 07:47 AM PST

Vaccine Against Alzheimer's to Hit Clinical Trials

WRITTEN BY: Annie Lennon

Currently Alzheimer’s disease is thought to affect around 50 million people around the world, with this figure doubling every year. Currently with no cure and no guaranteed preventative strategy, within just a couple years, a vaccination to combat its primary causes may begin human trials. 

The development of a vaccine comes after the failure of many drugs designed to reduce the build-up of amyloid protein and tau in the brain- thought to be the two primary causes of Alzheimer’s-related neurodegeneration. Whereas previous attempts to focus on reducing tau and amyloid accumulation separately have largely failed, researchers now believe that focusing on both simultaneously may hold more promise- as there is growing evidence suggesting a synergistic relationship between the two in driving neurodegeneration. 

Moreover, as most treatments targeting these protein build-ups have been more reactive than proactive, scientists from the Institute for Molecular Medicine and the University of California, Irvine, decided to work on vaccine-based measures to simultaneously prevent both of these toxic proteins from accumulating in the first place. 

For their study, they combined two existing vaccines, known as AV-1959R and AV-1980R, designed respectively to target amyloid and tau protein build-ups. The vaccine itself was delivered via a novel adjuvant known as Advax, a delivery method designed to improve the efficacy of any therapy. 

Nikolai Petrovsky, one of the scientists being Advax and a researcher at Australia’s Flinders University, said, “Our approach is looking to cover all the bases and get past previous roadblocks in finding a therapy to slow the accumulation of Aβ/tau molecules and delay AD progression in a rising number of people around the world.

Aiming for the vaccine to hit human clinical trials within two years, Petrovsky continued, “In the animal models, we can both use it to prevent the development of memory loss by giving it before the animal starts to get these build-ups of proteins...But we can also show that even when we give it after the animals have proteins, we can actually get rid of the abnormal proteins.”

"It's an exciting time to be starting the new decade – hopefully this is the breakthrough of the next decade if we can get it to work in human trials.”


 

Sources: New Atlas, EPM Magazine and Study Finds

 

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
JAN 20, 2020
Health & Medicine
JAN 20, 2020
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
JAN 20, 2020
Drug Discovery & Development
JAN 20, 2020
Discovery of mechanism behind Alexander disease may lead to enhanced drug development
Researchers have long known that the cause behind Alexander disease is a genetic culprit—mainly a mutation leading to the production of a defective p...
JAN 20, 2020
Drug Discovery & Development
JAN 20, 2020
Parkinson's Drug Reduces Hallucinations in Dementia Patients
Pimavanserin, also known as Nuplazid, was approved in the US to treat Parkinson’s-related psychosis in 2016. Now, new research has shown that it also...
JAN 20, 2020
Drug Discovery & Development
JAN 20, 2020
A tool that simplifies the hunt for cancer drugs
Cells have long been the internal hubs for proteins that hold a wide variety of unique functions. Disorders on how a cell synthesizes a protein can affect ...
JAN 20, 2020
Drug Discovery & Development
JAN 20, 2020
Improving Vaccines for Meningitis
Scientists at the University of Nottingham are seeking new ways to improve vaccine use in the protection against the bacterium, Neisseria meningitides that...
JAN 20, 2020
Drug Discovery & Development
JAN 20, 2020
Fatty Acid Supplement Repairs Brain After Stroke in Mice
Researchers have found that supplements containing short chain fatty acids (SCFAs) may be able to help the brain recover from having a stroke. This comes a...
Loading Comments...